Alzheimers Treatment

Hospitals

Foundations team up to fund translational research on mitochondrial diseases, Alzheimer’s

Two foundations are pairing up to fund work toward new treatments for a group of diseases caused by mitochondrial dysfunction. The Alzheimer’s Drug Discovery Foundation and Foundation for Mitochondrial Medicine will award up to $200,000 to non-profit academic institutions and for-profit biotech companies. Qualifying organizations and companies should be conducting translational research for therapies that […]

presented by
Devices & Diagnostics

One to watch: Medical device company says eye test can diagnose Alzheimer’s

Cognoptix, Inc. claims to have created a working, in-office, non-invasive eye-scan that detects Alzheimer’s earlier in patients. The SAPPHIRE II tracks a beta amyloid (“Ab”) signature in the eyes of potential Alzheimer’s patients. In a 10-subject, proof-of-concept clinical trial, the drug-device picked up a 200 percent differentiation factor between five healthy volunteers and five patients […]

Daily

J&J and Atlas Venture back launch of drug developer using epigenetics to treat Alzheimer’s disease

Johnson & Johnson (NYSE: JNJ) kicked off the launch of its Boston innovation center with news that it is backing a new drug developer targeting Alzheimer’s disease and other neurological disorders. Early stage life science investor Atlas Venture started Rodin Therapeutics with biotechnology company Proteros and secured backing from J&J’s venture arm. Rodin is using epigenetics […]

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Pharma

Potential disease-altering drug for Alzheimer’s draws $6.4 million, with IND planned for 2014

A preclinical drug aimed at preventing misfolded proteins from getting tangled in the brain and potentially causing neurodegenerative disease has drawn another $6.4 million from investors. The latest round for NeuroPhage Pharmaceuticals was led by Merieux Developpement, the private equity arm of the French public health group Institut Merieux. NeuroPhage says all existing investors also […]